As more gene therapies near approval, optimizing lentiviral vector (LV) production is becoming ever more important. Current production methods, however, are inefficient in terms of time and resources.

The advent of gene therapy has unlocked new possibilities for treating diseases previously regarded as intractable. However, producing adeno-associated virus (AAV)-mediated gene therapy products ...

Whether you're welcoming home a new baby, flying to a new destination for a vacation or working around sick patients as a doctor or nurse, your immunity is your invisible armor against all the bugs ...

Caused by the worldwide spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the coronavirus disease 2019 (COVID-19) pandemic continues to damage global public health and economic ...

Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced a licensing agreement for its CHO Edge System with RevOpsis Therapeutics ("RevOpsis"), a ...

Gene therapy is a rapidly growing area for therapeutic development, due to the potential to cure a wide range of genetic disorders. Although gene therapy has been around for many years, advances in ...

The ExpiCHO and Expi293 transient expression systems offer all-in-one solutions for generating high-titer recombinant proteins for a broad range of research applications including candidate drug ...

High-titer convalescent plasma was compared with placebo in older adult patients within the first 3 days after the onset of symptoms of Covid-19 and documented SARS-CoV-2 infection. Disease ...

Decreased AChR-Ab titers correlated with improved myasthenia gravis symptoms, especially in ADL scores, within the first 3 months of treatment. The study found no baseline correlation between AChR-Ab ...